Inhibition by luciferin-luciferase reagents of aggregatory responses to excitatory agonists in washed platelet suspensions.
Addition of two commercial luciferin-luciferase reagents caused marked inhibition of the aggregatory response of washed human platelets to thrombin, ADP, vasopressin and platelet-activating factor (PAF). Analysis of the effects of the individual components of one of these reagents revealed that Mg2+, and to a lesser extent bovine serum albumin, was responsible for the observed inhibition. A modified luciferin/luciferase reagent has been designed on the basis of these data for use in washed platelet suspensions which causes minimal inhibition of the aggregatory and secretory responses to thrombin but which gives a near maximal luminescence yield.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000378:metabolism; D049454:Firefly Luciferin / Q000494:pharmacology*; D006801:Humans; D008156:Luciferases / Q000494:pharmacology*; D008274:Magnesium / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D013917:Thrombin / Q000494:pharmacology; D014667:Vasopressins / Q000494:pharmacology
D014667:Vasopressins; D049454:Firefly Luciferin; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D008156:Luciferases; D013917:Thrombin; D008274:Magnesium